C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 5.89 HKD -2.32%
Market Cap: 2.1B HKD

Wall Street
Price Targets

Price Targets Summary
Cutia Therapeutics

Wall Street analysts forecast Cutia Therapeutics stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Cutia Therapeutics is 13.43 HKD with a low forecast of 9.4 HKD and a high forecast of 15.96 HKD.

Lowest
Price Target
9.4 HKD
60% Upside
Average
Price Target
13.43 HKD
128% Upside
Highest
Price Target
15.96 HKD
171% Upside
Cutia Therapeutics Competitors:
Price Targets
PHIL
Philogen SpA
14% Upside
URGN
Urogen Pharma Ltd
65% Upside
ARQT
Arcutis Biotherapeutics Inc
11% Upside
CCCC
C4 Therapeutics Inc
390% Upside
251120
Bio-FD&C Co Ltd
22% Upside
4587
PeptiDream Inc
101% Upside
2142
Hbm Holdings Ltd
2% Upside
VCYT
Veracyte Inc
15% Upside

Revenue
Forecast

Revenue Estimate
Cutia Therapeutics

For the last 2 years the compound annual growth rate for Cutia Therapeutics's revenue is 396%. The projected CAGR for the next 4 years is 63%.

396%
Past Growth
63%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Cutia Therapeutics

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Cutia Therapeutics

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Cutia Therapeutics's stock price target?
Price Target
13.43 HKD

According to Wall Street analysts, the average 1-year price target for Cutia Therapeutics is 13.43 HKD with a low forecast of 9.4 HKD and a high forecast of 15.96 HKD.

What is Cutia Therapeutics's Revenue forecast?
Projected CAGR
63%

For the last 2 years the compound annual growth rate for Cutia Therapeutics's revenue is 396%. The projected CAGR for the next 4 years is 63%.

Back to Top